Jasper Therapeutics, Inc. (JSPR), a Redwood City, California-based clinical-stage biotechnology company, has become one of the more volatile micro-cap names in the healthcare sector. After a 1-for-30 reverse stock split, a transformative acquisition, and a sharp year-long decline, the central question is whether shares can climb back toward $75 — a reference level far above the latest price. JSPR does not currently have enough clean, post-split analyst targets to support a meaningful consensus, so this analysis uses a fallback reference level rather than forcing an analyst average. The most recent individual targets were issued before the November 2026 reverse split: Piper Sandler set a $2.00 target (Overweight, Aug. 12, 2026), RBC Capital set $3.00 (Hold, May 14, 2026), and UBS last published $1.50 (Neutral, March 23, 2026, before moving to No Rating in September). Adjusting these for the 1-for-30 split yields roughly $60, $90, and $45, respectively — a $45 to $90 range. The mean of the two still-active targets ($60 and $90) is $75. Notably, a "$600" consensus circulating on some data platforms appears to be a mechanical multiplication artifact of a pre-split target and is not used here. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
JSPR closed near $11.77 on Nov. 16, 2026, down sharply after third-quarter results, following a 1-for-30 reverse split that reduced shares outstanding to about 1.1 million. Reaching $75 requires a roughly 537% advance — a very large move for any stock, and especially demanding for a pre-revenue biotech. The company completed its all-stock acquisition of Kira Pharmaceuticals in July 2026 and raised approximately $132 million in a concurrent private placement, leaving about $135.3 million in cash at Sept. 30, 2026. Management says this funds operations into the second half of 2028, but the path toward a higher valuation hinges almost entirely on clinical data and regulatory milestones rather than near-term earnings.
The most important supports are pipeline catalysts. KP-104 (vensobafusp alfa), a dual-complement inhibitor, is being evaluated in a Phase 2 renal basket study, with interim Stage 1 data in IgA nephropathy (a kidney disease) expected in the fourth quarter of 2026. Briquilimab, an anti-KIT antibody, is advancing toward a pre-BLA (Biologics License Application) meeting with the FDA for severe combined immunodeficiency, with next steps expected in early 2027. The company also plans an IND (Investigational New Drug) filing for KP-701 in early 2027 and an end-of-Phase 2 meeting for KP-104 in PNH (paroxysmal nocturnal hemoglobinuria) in the first half of 2027. Positive data could justify a re-rating, and the strengthened balance sheet reduces near-term financing overhang.
The risks are substantial. JSPR generates no meaningful product revenue and reported a large third-quarter net loss, including acquisition-related charges. At a roughly $13 million market capitalization with a thin float, the stock is highly illiquid and vulnerable to sharp swings. Shareholders also approved an increase in authorized shares to 675 million, signaling possible future dilution. The reverse stock split itself is typically a response to listing-compliance pressure and reflects the stock's roughly 74% decline over the trailing year. Finally, binary clinical readouts, regulatory delays, and competition in chronic urticaria and PNH could all weigh on sentiment.
Post-split technical structure is limited because the float is tiny and the split distorted historical chart levels. The stock has traded in a post-split range with a low near $9.45, and the $10 area acts as a nearby psychological support zone. No durable resistance has been established above the current price, meaning any sustained advance would need to build new levels on fundamental catalysts rather than established technical support.
Analyst price targets generally reflect a roughly 12-month research horizon, but the targets referenced here predate both the Kira acquisition and the reverse split, so their applicability is limited. Investors should monitor the KP-104 Stage 1 renal data expected in the fourth quarter of 2026, the briquilimab pre-BLA meeting and KP-701 filing in early 2027, any further financing or dilution, and Nasdaq listing-compliance developments. These events, more than short-term price action, are likely to determine whether a move toward $75 becomes realistic. From what I see, monitoring these milestones closely makes sense given the binary nature of biotech catalysts.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap such as JSPR, where fundamentals shift quickly and traditional valuation tools are limited, these signals can help traders discover opportunities, monitor positions, and identify changing trends more efficiently. I find them useful for framing setups in names like this where data moves fast.
The $75 level is a fallback reference point — the reverse-split-adjusted average of two still-active analyst targets — not a published consensus, and it sits far above the roughly $11.77 market price, requiring a very large move of about 537%. The strongest supports are a strengthened balance sheet, an expanded pipeline, and a dense schedule of 2026–2027 catalysts; the principal obstacles are a lack of revenue, heavy losses, dilution risk, and stale analyst coverage that has not been refreshed for the reverse split or the Kira acquisition. Because the analyst range is extremely wide, investors should treat $75 as a conceptual upside scenario rather than a forecast, and focus on the clinical data releases ahead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
JSPR saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 84 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for JSPR turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 34 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JSPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for JSPR entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +6.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where JSPR advanced for three days, in 203 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
JSPR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. JSPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: JSPR's P/B Ratio (397.034) is very high in comparison to the industry average of (3.498). P/E Ratio (-18.129) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JSPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology